Your Health, We Care
Balversa is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Balversa.
Balversa is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.
from FDA,2024.01
Balversais a new target anti-cancer star, specializing in FGFR-positive cancers, providing patients with precision treatment options, although effective, it is necessary to pay att···【more】
Article source：Lucius LaosRelease date：2024-08-26Recommended：127
Balversa, an innovative anti-cancer targeted drug, accurately snipes FGFR-positive tumors and opens up new hope for patients with advanced cancer.What diseases is Balversasuitable ···【more】
Article source：Lucius LaosRelease date：2024-08-26Recommended：106
Balversa is an innovative targeted therapy that effectively inhibits the growth of cancer cells for FGFR-positive tumors, bringing new treatment options to patients, but they need ···【more】
Article source：Lucius LaosRelease date：2024-08-26Recommended：125
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
